Malaysia Intravenous Immunoglobulin (IVIG) Market

Executive Summary

Malaysia Intravenous Immunoglobulin (IVIG) Market was valued at US $11.83 billion in 2021 and is projected to grow at 6.60% CAGR over the forecast period to reach US $17.37 billion by 2027. Malaysia Intravenous Immunoglobulin (IVIG) Market represented US $1.42 billion opportunity over 2019-2021 and estimated to create US $5.53 billion opportunity in 2027 over 2021.

Malaysia Intravenous Immunoglobulin (IVIG) from Consainsights analyses the Malaysia Intravenous Immunoglobulin (IVIG) Market in the Life Sciences industry over the forecast period to 2027.

Malaysia Intravenous Immunoglobulin (IVIG) research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Malaysia Intravenous Immunoglobulin (IVIG) segmentation includes Application, Product, Mode Of Delivery, Concentration and Geography.

Based on the Application, the Malaysia Intravenous Immunoglobulin (IVIG) analysis covers HYPOGAMMAGLOBULINEMIA, CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD), IMMUNODEFICIENCY DISEASES (ID), MYASTHENIA GRAVIS (MG), MULTIFOCAL MOTOR NEUROPATHY (MMN), PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP), INFLAMMATORY MYOPATHIES (IM), SPECIFIC ANTIBODY DEFICIENCY (SAD), GUILLAIN-BARR SYNDROME (GBS), KAWASAKI DISEASE (KD), SECONDARY IMMUNE DEFICIENCY (SID), OTHERS.

In Application segment, HYPOGAMMAGLOBULINEMIA segment has highest cagr growth of 5.85%.

Based on the Product, the Malaysia Intravenous Immunoglobulin (IVIG) analysis covers IGA, IGM, IGE, IGD.

In Product segment, IGA segment has highest cagr growth of 5.85%.

Based on the Mode Of Delivery, the Malaysia Intravenous Immunoglobulin (IVIG) analysis covers INTRAVENOUS MODE OF DELIVERY, SUBCUTANEOUS MODE OF DELIVERY, INTRAMUSCULAR MODE OF DELIVERY.

In Mode Of Delivery segment, INTRAVENOUS MODE OF DELIVERY segment has highest cagr growth of 5.85%.

Based on the Concentration, the Malaysia Intravenous Immunoglobulin (IVIG) analysis covers 5% CONCENTRATION, 10% CONCENTRATION, OTHER CONCENTRATIONS.

In Concentration segment, 5% CONCENTRATION segment has highest cagr growth of 5.85%.

Based on the region, the Malaysia Intravenous Immunoglobulin (IVIG) analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include BAXTER INTERNATIONAL INC., BAYER AG, BIOTEST AG, CSL LTD., GREEN CROSS CORPORATION, GRIFOLS S.A., JOHNSON & JOHNSON, KEDRION S.P.A., OCTAPHARMA AG, SHIRE PLC and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Application

Introduction

In 2021, HYPOGAMMAGLOBULINEMIA segment has the highest revenue of US $4.54 billion and is expected to grow at CAGR of 5.85% by 2027 HYPOGAMMAGLOBULINEMIA segment has highest cagr growth of 5.85%.

HYPOGAMMAGLOBULINEMIA

HYPOGAMMAGLOBULINEMIA segment was valued at US $4.00 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $6.67 billion by 2027. HYPOGAMMAGLOBULINEMIA segment represented US $0.55 billion opportunity over 2019-2021 and estimated to create US $2.12 billion opportunity in 2027 over 2021.

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD)

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD) segment was valued at US $2.48 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $4.13 billion by 2027. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD) segment represented US $0.34 billion opportunity over 2019-2021 and estimated to create US $1.32 billion opportunity in 2027 over 2021.

IMMUNODEFICIENCY DISEASES (ID)

IMMUNODEFICIENCY DISEASES (ID) segment was valued at US $1.52 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $2.54 billion by 2027. IMMUNODEFICIENCY DISEASES (ID) segment represented US $0.21 billion opportunity over 2019-2021 and estimated to create US $0.81 billion opportunity in 2027 over 2021.

MYASTHENIA GRAVIS (MG)

MYASTHENIA GRAVIS (MG) segment was valued at US $0.96 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $1.60 billion by 2027. MYASTHENIA GRAVIS (MG) segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.51 billion opportunity in 2027 over 2021.

MULTIFOCAL MOTOR NEUROPATHY (MMN)

MULTIFOCAL MOTOR NEUROPATHY (MMN) segment was valued at US $0.57 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.96 billion by 2027. MULTIFOCAL MOTOR NEUROPATHY (MMN) segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.31 billion opportunity in 2027 over 2021.

PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP)

PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP) segment was valued at US $0.35 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.59 billion by 2027. PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP) segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

INFLAMMATORY MYOPATHIES (IM)

INFLAMMATORY MYOPATHIES (IM) segment was valued at US $0.22 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.36 billion by 2027. INFLAMMATORY MYOPATHIES (IM) segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.12 billion opportunity in 2027 over 2021.

SPECIFIC ANTIBODY DEFICIENCY (SAD)

SPECIFIC ANTIBODY DEFICIENCY (SAD) segment was valued at US $0.12 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.20 billion by 2027. SPECIFIC ANTIBODY DEFICIENCY (SAD) segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.06 billion opportunity in 2027 over 2021.

GUILLAIN-BARR SYNDROME (GBS)

GUILLAIN-BARR SYNDROME (GBS) segment was valued at US $0.07 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.12 billion by 2027. GUILLAIN-BARR SYNDROME (GBS) segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

KAWASAKI DISEASE (KD)

KAWASAKI DISEASE (KD) segment was valued at US $0.05 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.08 billion by 2027. KAWASAKI DISEASE (KD) segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.

SECONDARY IMMUNE DEFICIENCY (SID)

SECONDARY IMMUNE DEFICIENCY (SID) segment was valued at US $0.04 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.07 billion by 2027. SECONDARY IMMUNE DEFICIENCY (SID) segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.03 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $0.04 billion by 2027. OTHERS segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Product

Introduction

In 2021, IGA segment has the highest revenue of US $4.91 billion and is expected to grow at CAGR of 5.85% by 2027 IGA segment has highest cagr growth of 5.85%.

IGA

IGA segment was valued at US $4.32 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $7.21 billion by 2027. IGA segment represented US $0.59 billion opportunity over 2019-2021 and estimated to create US $2.30 billion opportunity in 2027 over 2021.

IGM

IGM segment was valued at US $3.00 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $5.01 billion by 2027. IGM segment represented US $0.41 billion opportunity over 2019-2021 and estimated to create US $1.60 billion opportunity in 2027 over 2021.

IGE

IGE segment was valued at US $1.58 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $2.63 billion by 2027. IGE segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.84 billion opportunity in 2027 over 2021.

IGD

IGD segment was valued at US $1.51 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $2.51 billion by 2027. IGD segment represented US $0.21 billion opportunity over 2019-2021 and estimated to create US $0.80 billion opportunity in 2027 over 2021.

Mode Of Delivery

Introduction

In 2021, INTRAVENOUS MODE OF DELIVERY segment has the highest revenue of US $5.15 billion and is expected to grow at CAGR of 5.85% by 2027 INTRAVENOUS MODE OF DELIVERY segment has highest cagr growth of 5.85%.

INTRAVENOUS MODE OF DELIVERY

INTRAVENOUS MODE OF DELIVERY segment was valued at US $4.53 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $7.56 billion by 2027. INTRAVENOUS MODE OF DELIVERY segment represented US $0.62 billion opportunity over 2019-2021 and estimated to create US $2.41 billion opportunity in 2027 over 2021.

SUBCUTANEOUS MODE OF DELIVERY

SUBCUTANEOUS MODE OF DELIVERY segment was valued at US $3.15 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $5.25 billion by 2027. SUBCUTANEOUS MODE OF DELIVERY segment represented US $0.43 billion opportunity over 2019-2021 and estimated to create US $1.67 billion opportunity in 2027 over 2021.

INTRAMUSCULAR MODE OF DELIVERY

INTRAMUSCULAR MODE OF DELIVERY segment was valued at US $2.74 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $4.57 billion by 2027. INTRAMUSCULAR MODE OF DELIVERY segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.45 billion opportunity in 2027 over 2021.

Concentration

Introduction

In 2021, 5% CONCENTRATION segment has the highest revenue of US $7.41 billion and is expected to grow at CAGR of 5.85% by 2027 5% CONCENTRATION segment has highest cagr growth of 5.85%.

5% CONCENTRATION

5% CONCENTRATION segment was valued at US $6.52 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $10.88 billion by 2027. 5% CONCENTRATION segment represented US $0.89 billion opportunity over 2019-2021 and estimated to create US $3.47 billion opportunity in 2027 over 2021.

10% CONCENTRATION

10% CONCENTRATION segment was valued at US $1.82 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $3.03 billion by 2027. 10% CONCENTRATION segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $0.97 billion opportunity in 2027 over 2021.

OTHER CONCENTRATIONS

OTHER CONCENTRATIONS segment was valued at US $2.07 billion in 2019 and is projected to grow at 5.85% CAGR over the forecast period to reach US $3.46 billion by 2027. OTHER CONCENTRATIONS segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $1.10 billion opportunity in 2027 over 2021.